Wright Medical Group, Inc. to Present at the 31st Annual J.P. Morgan Healthcare Conference

  Wright Medical Group, Inc. to Present at the 31st Annual J.P. Morgan
  Healthcare Conference

              Monday, January 7, 2013 at 2:30 p.m. Pacific Time

JPMorgan Healthcare Conference 2013

Business Wire

ARLINGTON, Tenn. -- December 27, 2012

Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device
company, announced today that it will be participating in the 31^st Annual
J.P. Morgan Healthcare Conference on Monday, January 7, 2013, at the Westin
St. Francis Hotel in San Francisco, California. Robert Palmisano, President
and Chief Executive Officer, will present at 2:30 p.m. Pacific Time.

A live audio webcast of the conference presentation, along with the
accompanying presentation materials, will be available on Wright’s corporate
website at www.wmt.com/corporate, under the “Investor Info” link. The audio
webcast and accompanying presentation materials will be archived on this site
under the “Investor Presentations” link following the conference.

About Wright Medical

Wright Medical Group, Inc. is a global orthopaedic medical device company that
specializes in the design, manufacture and marketing of devices and biologics
for extremity, hip and knee reconstruction and is the recognized leader of
surgical solutions for the foot and ankle market. The Company has been in
business for more than 60 years and markets its products in over 60 countries
worldwide. For more information about Wright Medical, visit the Company’s
website at www.wmt.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation and webcast may contain “forward-looking statements” as
defined under U.S. federal securities laws. These statements reflect
management’s current knowledge, assumptions, beliefs, estimates, and
expectations and express management’s current view of future performance,
results, and trends. Forward looking statements may be identified by their use
of terms such as anticipate, believe, could, estimate, expect, intend, may,
plan, predict, project, will, and other similar terms. Forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results to materially differ from those described in the
forward-looking statements. In addition to those described below, forward
looking statements contained in this presentation and webcast include, without
limitation, statements concerning the timing and expected benefits of the
previously announced merger agreement with BioMimetic Therapeutics, Inc.,
including statements about the possibility of FDA approval of Augment Bone
Graft, statements regarding market acceptance of, and expected annual market
demand for Augment Bone Graft, and statements regarding the expected impact of
the transaction on Wright’s adjusted EBITDA and other financial results. The
reader should not place undue reliance on forward-looking statements. Such
statements are made as of the date of this presentation and webcast, and we
undertake no obligation to update such statements after this date. In addition
to those described above, risks and uncertainties that could cause our actual
results to materially differ from those described in forward-looking
statements are discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on Form
10-K for the year ended December 31, 2011 and our Quarterly Report on Form
10-Q for the quarter ended September 30, 2012, in each case under the heading
“Risk Factors” and elsewhere in such filings). By way of example and without
implied limitation, such risks and uncertainties include: the failure of
BioMimetic stockholders to adopt the merger agreement or the failure of either
Wright or BioMimetic to meet any of the other conditions to the closing of the
transaction, the failure to realize the anticipated benefits from the
transaction or delay in realization thereof, future actions of the United
States Attorney’s office, the FDA, the Department of Health and Human Services
or other U.S. or foreign government authorities that could delay, limit or
suspend our development, manufacturing, commercialization and sale of
products, or result in seizures, injunctions, monetary sanctions or criminal
or civil liabilities; any actual or alleged breach of the Corporate Integrity
Agreement to which we are subject through September 2015 which could expose us
to significant liability including exclusion from Medicare, Medicaid and other
federal healthcare programs, potential criminal prosecution, and civil and
criminal fines or penalties; adverse outcomes in existing product liability
litigation; new product liability claims; inadequate insurance coverage; the
possibility of private securities litigation or shareholder derivative suits;
demand for and market acceptance of our new and existing products; potentially
burdensome tax measures; lack of suitable business development opportunities;
product quality or patient safety issues; challenges to our intellectual
property rights; geographic and product mix impact on our sales; our inability
to retain key sales representatives, independent distributors and other
personnel or to attract new talent; inventory reductions or fluctuations in
buying patterns by wholesalers or distributors; inability to realize the
anticipated benefits of restructuring initiatives; negative impact of the
commercial and credit environment on us, our customers and our suppliers; and
the potentially negative effect of our ongoing compliance enhancements on our
relationships with customers, and on our ability to deliver timely and
effective medical education, clinical studies, and new products.

ADDITIONAL INFORMATION ABOUT THIS TRANSACTION

This presentation and webcast may be deemed to be solicitation material
regarding the proposed business combination of Wright and BioMimetic. In
connection with the proposed transaction, Wright has filed with the SEC a
registration statement on Form S-4, which includes a proxy
statement/prospectus and other relevant materials in connection with the
proposed transaction, and each of Wright and BioMimetic intend to file with
the SEC other documents regarding the proposed transaction. The proxy
statement/prospectus and this presentation and webcast are not offers to sell
Wright securities and are not soliciting an offer to buy Wright securities in
any state where the offer and sale is not permitted. The final proxy
statement/prospectus will be mailed to the stockholders of BioMimetic.
INVESTORS AND SECURITY HOLDERS OF BIOMIMETIC ARE URGED TO READ THE PROXY
STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND THE
OTHER RELEVANT MATERIAL CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT WRIGHT AND BIOMIMETIC
AND THE PROPOSED TRANSACTION.

The proxy statement/prospectus and other relevant materials (when they become
available), and any and all documents filed with the SEC, may be obtained free
of charge at the SEC’s web site at www.sec.gov. In addition, investors and
security holders may obtain free copies of the documents filed with the SEC by
Wright by directing a written request to Wright Medical Group, Inc, 5677
Airline Road, Arlington, TN 38002, Attention: Investor Relations, and by
BioMimetic by directing a written request to BioMimetic Therapeutics, Inc.,
389 Nichol Mill Lane, Franklin, TN 37067, Attention: Investor Relations.

BioMimetic and its respective executive officers and directors and other
persons, including Wright and its respective executive officers and directors,
may be deemed to be participants in the solicitation of proxies from its
stockholders in connection with the proposed transaction. Information about
the executive officers and directors of BioMimetic and their ownership of
BioMimetic common stock is set forth in its annual report on Form 10-K for the
year ended December 31, 2011, filed with the SEC on March 13, 2012 and the
proxy statement for BioMimetic’s 2012 annual meeting of stockholders, filed
with the SEC on April 27, 2012. Information about the executive officers and
directors of Wright Medical Group is set forth in its annual report on Form
10-K for the year ended December 31, 2011, filed with the SEC on February 24,
2012 and the proxy statement for Wright Medical Group’s 2012 annual meeting of
stockholders, filed with the SEC on March 27, 2012. Certain directors and
executive officers of BioMimetic and other persons may have direct or indirect
interests in the merger due to securities holdings, pre-existing or future
indemnification arrangements and rights to severance payments if their
employment is terminated prior to or following the transaction. If and to the
extent that any of the BioMimetic participants will receive any additional
benefits in connection with the transaction, the details of those benefits
will be described in the proxy statement/prospectus relating to the
transaction. Investors and security holders may obtain additional information
regarding the direct and indirect interests of BioMimetic and its executive
officers and directors in the transaction.

Contact:

Wright Medical Group, Inc.
Julie D. Tracy, 901-290-5817
Sr. Vice President, Chief Communications Officer
julie.tracy@wmt.com
 
Press spacebar to pause and continue. Press esc to stop.